🇫🇷 Version française

EU AI Act for PE Deal Teams.

Acquisitions are pricing in AI assets. The AI Act determines whether those assets are legally usable. Most pre-LOI reviews are not asking the right questions.

The EU AI Act entered into force in August 2024. Its obligations phase in over a 36-month timeline, with the most consequential deadline for PE-backed companies landing on August 2, 2026. That is when high-risk AI system requirements become enforceable. For acquirers building deal theses around AI capabilities, proprietary models, or data-driven personalization, this deadline changes the risk calculus in ways that standard diligence does not capture.

What we see consistently in pre-LOI reviews: deal teams pricing AI assets at a premium without validating whether the training data meets Article 10 requirements for data governance. The model may be technically impressive. The data underneath it may be legally unusable under the AI Act, under GDPR, or under both. That gap between technical capability and legal usability is where deal value evaporates.

The AI Act does not exist in isolation. It intersects with GDPR on consent architecture. It intersects with sector-specific regulation on high-risk classification. It creates documentation and transparency obligations that retroactively apply to systems already in production. For PE acquirers, the question is not whether a target company uses AI. The question is whether the AI assets survive regulatory contact.

Field observation In three separate diligence engagements over the past six months, we found AI-powered recommendation engines trained on user behavioral data collected under cookie consent banners that did not cover model training as a processing purpose. The AI asset was real. The legal basis for the training data was not. In each case, the remediation cost exceeded the projected first-year value of the AI capability.

This hub covers the specific AI Act obligations that affect PE deal flow: risk classification for AI systems commonly found in portfolio companies, training data requirements that intersect with existing privacy regulation, the August 2026 compliance deadline, and the MarTech-specific obligations that apply to AI-powered marketing tools. Each section is built for deal teams, not regulators. The focus is on what creates acquisition risk and what the remediation path looks like.

Key Signals

AI Act Exposure Signals
in Pre-LOI Review

AI models trained on user data without documented legal basis for training use

Article 10 requires documented data governance for training datasets. When the original data collection did not contemplate model training as a purpose, the entire dataset may need to be re-consented or replaced. This is not a theoretical risk. It is a balance sheet item.

No risk classification assessment for AI systems in production

The AI Act applies different obligation tiers based on risk classification. Most portfolio companies have not assessed which tier their AI systems fall into. Systems that touch credit scoring, employment decisions, or biometric processing are likely high-risk, with full compliance requirements by August 2026.

No transparency documentation for customer-facing AI systems

Articles 13 and 52 impose transparency obligations on AI systems that interact with humans. Chatbots, recommendation engines, and automated decision-making tools all require disclosure. Companies without this documentation face both regulatory exposure and buyer scrutiny during diligence.

GDPR consent architecture that does not extend to AI training use cases

The AI Act and GDPR are enforced by different authorities but share a data subject. When consent was collected for "personalization" but the data is used for model training, the legal basis gap creates exposure under both regulations simultaneously. This dual-exposure scenario is the most common finding in our AI-focused diligence work.

Next Step

Get the AI Act exposure assessment.

We scope the AI Act compliance gap, quantify the remediation cost, and map it against the deal timeline. Typically completed within two weeks of intake.

Request a Briefing →